- Home
- GNRC vs CORT Comparison
GNRC vs CORT Comparison
Compare GNRC & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNRC | CORT |
|---|---|---|
| Founded | 1959 | 1998 |
| Country | United States | United States |
| Employees | 9400 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 3.7B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | GNRC | CORT |
|---|---|---|
| Price | $219.03 | $35.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 6 |
| Target Price | ★ $195.56 | $105.20 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $17.03 | $30.63 |
| Revenue Next Year | $10.88 | $31.61 |
| P/E Ratio | $84.89 | ★ $43.02 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $104.90 | $28.66 |
| 52 Week High | $241.09 | $117.33 |
Technical Indicators
Market Signals| Indicator | GNRC | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 57.77 | 37.91 |
| Support Level | $136.22 | $33.53 |
| Resistance Level | $238.55 | $41.92 |
| Average True Range (ATR) | 10.11 | 2.54 |
| MACD | -2.19 | 0.38 |
| Stochastic Oscillator | 18.15 | 57.59 |
Price Performance
Historical ComparisonAbout GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.